Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

ClinicalTrials.gov ID: NCT05815758

Public ClinicalTrials.gov record NCT05815758. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution, Used Two Times Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)

Study identification

NCT ID
NCT05815758
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bausch & Lomb Incorporated
Industry
Enrollment
512 participants

Conditions and interventions

Interventions

  • Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo) Drug
  • Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution Drug

Drug

Eligibility (public fields only)

Age range
5 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 19, 2023
Primary completion
Sep 17, 2023
Completion
Sep 17, 2023
Last update posted
Jul 9, 2025

2023

United States locations

U.S. sites
7
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
104- Arizona Eye Center Chandler Arizona 85225
103- Seidenberg Protzko Eye Associates Havre de Grace Maryland 21078
101 - Andover Eye Associates Andover Massachusetts 01810
105- NC Eye Associates Apex North Carolina 27502
107 Total Eye Care, PA Memphis Tennessee 38119
106- Emerson Research Institute, Inc. Falls Church Virginia 22046
102 - Piedement Eye Center Lynchburg Virginia 24502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05815758, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 9, 2025 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05815758 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →